Digest Réseau Comment ça marche
Réseau
/
Sociétés
F.
Non vérifié

F. Hoffmann-La Roche Ltd

Ce que nous écrivons

Annonces ÉconomiquesIndustrie pharmaceutiquePublicité/Marketing/Médias/Communication

163 communiqués de presse

Voir tous les communiqués de presse
30/09/2026
Industrie pharmaceutique
Annonces Économiques
Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
30/09/2026
Industrie pharmaceutique
Annonces Économiques
Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
29/09/2026
Industrie pharmaceutique
Annonces Économiques
Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
22/09/2026
Industrie pharmaceutique
Annonces Économiques
Publicité/Marketing/Médias/Communication
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
22/09/2026
Industrie pharmaceutique
Annonces Économiques
Change in Roche’s Board of Directors
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
21/09/2026
Industrie pharmaceutique
Annonces Économiques
Publicité/Marketing/Médias/Communication
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
21/09/2026
Industrie pharmaceutique
Annonces Économiques
Publicité/Marketing/Médias/Communication
European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
18/09/2026
Industrie pharmaceutique
Annonces Économiques
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
17/09/2026
Industrie pharmaceutique
Annonces Économiques
Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
16/09/2026
Industrie pharmaceutique
Annonces Économiques
Publicité/Marketing/Médias/Communication
Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0